drugset / Trial / NCT00574834
Mechanisms of Ramipril Reduction in the Onset of Type 2 Diabetes
Phase 0
Terminated
17 enrolled
University of Maryland, Baltimore
King Pharmaceuticals is now a wholly owned subsidiary of Pfizer · collab
RandomizedParallel-groupDouble-blindPrevention
Summary
The study will be focused on determining the integrated in-vivo mechanisms responsible for Ramipril's effects on delaying type 2 diabetes and restoring normal (blood sugar levels) glycemia in patients with impaired glucose tolerance. Hypothesis - Ramipril effects will delay the onset of type 2 diabetes and restore normal glycemia in patients with impaired glucose tolerance.
Timeline
- Start
- 2007-03
- Primary completion
- 2014-08
- Completion
- 2014-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Hydrochlorothiazide | Unknown | 25 mg | — |
| Comparator | Ramipril | Small molecule | 20 mg | — |